JP2009539877A5 - - Google Patents

Download PDF

Info

Publication number
JP2009539877A5
JP2009539877A5 JP2009514546A JP2009514546A JP2009539877A5 JP 2009539877 A5 JP2009539877 A5 JP 2009539877A5 JP 2009514546 A JP2009514546 A JP 2009514546A JP 2009514546 A JP2009514546 A JP 2009514546A JP 2009539877 A5 JP2009539877 A5 JP 2009539877A5
Authority
JP
Japan
Prior art keywords
diabetes
group
phenylacetic acid
composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009514546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009539877A (ja
JP5252585B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/070691 external-priority patent/WO2007146768A2/en
Publication of JP2009539877A publication Critical patent/JP2009539877A/ja
Publication of JP2009539877A5 publication Critical patent/JP2009539877A5/ja
Application granted granted Critical
Publication of JP5252585B2 publication Critical patent/JP5252585B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009514546A 2006-06-09 2007-06-08 代謝障害の治療のための化合物 Expired - Fee Related JP5252585B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80433606P 2006-06-09 2006-06-09
US60/804,336 2006-06-09
PCT/US2007/070691 WO2007146768A2 (en) 2006-06-09 2007-06-08 Compounds for the treatment of metabolic disorders

Publications (3)

Publication Number Publication Date
JP2009539877A JP2009539877A (ja) 2009-11-19
JP2009539877A5 true JP2009539877A5 (enExample) 2011-07-21
JP5252585B2 JP5252585B2 (ja) 2013-07-31

Family

ID=38832700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009514546A Expired - Fee Related JP5252585B2 (ja) 2006-06-09 2007-06-08 代謝障害の治療のための化合物

Country Status (12)

Country Link
US (1) US20100234464A1 (enExample)
EP (1) EP2026659A4 (enExample)
JP (1) JP5252585B2 (enExample)
KR (1) KR101391905B1 (enExample)
CN (1) CN101466266A (enExample)
AU (1) AU2007257854B2 (enExample)
CA (1) CA2654530A1 (enExample)
IL (1) IL195392A0 (enExample)
MX (1) MX2008015640A (enExample)
NZ (1) NZ573031A (enExample)
WO (1) WO2007146768A2 (enExample)
ZA (1) ZA200809774B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1978948A4 (en) * 2006-02-02 2010-06-16 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
US8481595B2 (en) * 2008-01-15 2013-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
DK2268141T3 (da) 2008-03-13 2019-07-29 Wellstat Therapeutics Corp Forbindelse og fremgangsmåde til at reducere urinsyre
RU2573933C1 (ru) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
JPWO2024005144A1 (enExample) 2022-07-01 2024-01-04

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60123665T2 (de) * 2000-12-26 2007-08-16 Sankyo Co., Ltd. Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
CZ20033394A3 (cs) * 2001-06-12 2005-03-16 Wellstat Therapeutics Corporation Sloučeniny pro léčení metabolických poruch a způsob jejich přípravy
AU2003286728A1 (en) * 2002-11-01 2004-06-07 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP2266946A3 (en) * 2003-02-13 2012-12-12 Wellstat Therapeutics Corporation Compound For The Treatment Of Metabolic Disorders
DE602004030004D1 (de) * 2003-04-15 2010-12-23 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
US7361686B2 (en) * 2003-04-22 2008-04-22 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1617835B1 (en) * 2003-04-30 2011-09-28 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CN1835743A (zh) * 2003-08-20 2006-09-20 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
EP1976377A4 (en) * 2006-01-25 2010-06-23 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
CA2636290A1 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Similar Documents

Publication Publication Date Title
JP2009537559A5 (enExample)
ES2752039T3 (es) Agente terapéutico para la dislipidemia
KR101860120B1 (ko) 글루코키나아제 활성화제와 병용되는 메트포르민의 용도, 및 메트포르민과 글루코키나아제 활성화제를 포함하는 조성물
JPH01503539A (ja) 非鎮静抗ヒスタミン薬を含んでなる咳／風邪用混合物
JP2009528275A5 (enExample)
TW200406204A (en) Combination of organic compounds
TW201136916A (en) New uses
CN104254325A (zh) 双胍组合物和治疗代谢性病症的方法
RU2005128501A (ru) Соединение для лечения метаболических расстройств
TW200305415A (en) Combination of organic compounds
CA2521621A1 (en) Compounds for the treatment of metabolic disorders
CA2522738A1 (en) Compounds for the treatment of metabolic disorders
JP2006514100A (ja) 徐放性ｌ−アルギニン製剤並びに製造方法および使用方法
JP2006524252A5 (enExample)
CA2502297A1 (en) Compounds for the treatment of metabolic disorders
JP5490409B2 (ja) スタチンおよびメチルニコチンアミド誘導体を含んでなるリポ蛋白質異常の処置用調剤
JP2009539877A5 (enExample)
CA2521589A1 (en) Compounds for the treatment of metabolic disorders
JP2004518756A (ja) Ｇｌｐ−１類似体およびｐｐａｒリガンドの誘導体の組み合わせ使用
EP1772149A1 (en) Drug for prevention or treatment of diabetes
EA015483B1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
JP2009524686A5 (enExample)
CN1777417A (zh) PPARα激动剂和二甲双胍降低血清甘油三酯的用途
WO2006001092A1 (ja) インスリン分泌促進剤
EP1550443A1 (en) Composition against stress-related diseases